RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
THIS RESEARCH COLLABORATION AGREEMENT (“Agreement”) is made and effective as the 20th day of December, 2018 (“Effective Date”), by and between APRINOIA Therapeutics Inc. (“APN”), a company having an office at 17F, No.3, Park St., Nangang District, Taipei City 11503, Taiwan, and H. Lundbeck A/S. (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA (each a “Party” and collectively, “Parties”).
Assignment AgreementAssignment Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Assignment Agreement (“Assignment Agreement”) is made and entered into effective as of the date of last signature below (the “Assignment Date”), by and among APRINOIA Therapeutics Inc. (Taiwan) (“Assignor”) with its principal place of business being 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan, APRINOIA Therapeutics Limited (Hong Kong) (“Assignee”) with its principal place of business being 31/F, Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong, H. Lundbeck A/S. (“Lundbeck”) with its principal place of business being Ottiliavej 9, 2500 Valby, Denmark and AbbVie Inc. (“AbbVie”) with its principal place of business being 1 N Waukegan Rd, North Chicago, IL, 60064 USA.
FIFTH AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Fifth Amendment (the “Fifth Amendment”), dated as of last signature on this agreement (“Fifth Amendment Effective Date”), to that certain Research Collaboration Agreement (the “Agreement”) dated as of December 20, 2018, is entered into by and among APRINOIA Therapeutics Limited (“APN”) with its principal place of business being 31/F, Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong, H. Lundbeck A/S (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA. APN, Lundbeck and AbbVie are each a “Party” and collectively, the “Parties”.
FOURTH AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Fourth Amendment (the “Fourth Amendment”), dated as of January 25, 2022 (“Fourth Amendment Effective Date”), to that certain Research Collaboration Agreement (the “Agreement”) dated as of December 20, 2018, is entered into by and among APRINOIA Therapeutics Limited (“APN”) with its principal place of business being 31/F, Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong, H. Lundbeck A/S (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA. APN, Lundbeck and AbbVie are each a “Party” and collectively, the “Parties”.
SIXTH AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Sixth Amendment (the “Sixth Amendment”), dated as of last signature on this agreement (“Sixth Amendment Effective Date”), to that certain Research Collaboration Agreement (the “Agreement”) dated as of December 20, 2018, is entered into by and among APRINOIA Therapeutics Limited (“APN”) with its principal place of business being 31/F, Chinachem Century Tower, 178 Gloucester Road, Wanchai, Hong Kong, H. Lundbeck A/S (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA. APN, Lundbeck and AbbVie are each a “Party” and collectively, the “Parties”.
SECOND AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Second Amendment (the “Second Amendment”), effective as December 1, 2019, to that certain Research Collaboration Agreement (the “Agreement” and incorporated herein by reference) effective December 20, 2018 and the First Amendment (the “First Amendment” and incorporated herein by reference) effective February 20, 2019, among APRINOIA Therapeutics Inc. (“APN”), a company having an office at 17F, No.3, Park St., Nangang District, Taipei City 11503, Taiwan, and H. Lundbeck A/S. (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA (each a “Party” and collectively, “Parties”).
THIRD AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTCertain • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This Third Amendment (the “Third Amendment”), effective as November 30, 2020, to that certain Research Collaboration Agreement (the “Agreement” and incorporated herein by reference) effective December 20, 2018, the First Amendment (the “First Amendment” and incorporated herein by reference) effective February 20, 2019 and the Second Amendment (the “Second Amendment” and incorporated herein by reference) effective December 1, 2019, among APRINOIA Therapeutics Inc. (“APN”), a company having an office at 17F, No.3, Park St., Nangang District, Taipei City 11503, Taiwan, and H. Lundbeck A/S. (“Lundbeck”), having an office at Ottiliavej 9, Valby, 2500, Denmark, and AbbVie Inc. (“AbbVie”), a company having an office at 1 N Waukegan Rd, North Chicago, IL, USA (each a “Party” and collectively, “Parties”).
FIRST AMENDMENT TO THE RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • February 26th, 2024 • APRINOIA Therapeutics Inc. • Pharmaceutical preparations
This First Amendment (the “First Amendment”), effective as February 20, 2019, to that certain Research Collaboration Agreement (the “Agreement” and incorporated herein by reference) effective December 20, 2018, among APRINOIA Therapeutics Inc. (“APN”), a company having an office at 17F, No.3, Park St., Nangang District, Taipei City 11503, Taiwan, and H. Lundbeck A/S (“Lundbeck’’), having an office at OttiIiavej 9, Valby, 2500, Denmark, and AbbVic Inc. (“AbbVic”), a company having an office at 1 N Waukegan Rd, North Chicago. IL, USA (each a “Party” and collectively, “Parties”).
